Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Nab-Paclitaxel Plus Pembrolizumab Produces Promising Responses in Advanced Urothelial Cancer

March 22nd 2022

Nab-paclitaxel plus pembrolizumab produced an encouraging overall response rate with manageable safety in patients with advanced urothelial cancer who were refractory to platinum-based chemotherapy or cisplatin ineligible, according to data from the phase 2 ABLE trial.

Dr. Iacovelli on Next Steps of the ARIES Trial in Urothelial Cancer

March 15th 2022

Roberto Iacovelli, MD, PhD, discusses the potential next steps of the phase 2 ARIES trial in urothelial cancer.

Neoadjuvant Chemotherapy Benefit Retains Stronghold for Patients With MIBC, UTUC

March 15th 2022

Effective treatment paths leveraging neoadjuvant chemotherapy have been well-established for patients with muscle-invasive bladder cancer, with mounting retrospective and prospective data continuing to demonstrate overall survival benefit compared with adjuvant chemotherapy.

Dr. Petrylak on the Rationale of the EV-103 Trial in MIBC

March 14th 2022

Daniel P. Petrylak, MD, discusses the rationale for of the phase 1b/2 EV-103 trial in patients with muscle-invasive bladder cancer.

Immunotherapy and Targeted Treatment Approaches Improve Outcomes in Metastatic Urothelial Cancer

March 14th 2022

Patients with metastatic urothelial carcinoma have multiple effective treatment options approved in both the first line and relapsed settings, with other promising agents and combinations currently in development.

Dr. Ramnaraign on Sequencing IO and TKI Combinations in Metastatic RCC

March 8th 2022

Brian Ramnaraign, MD, discusses sequencing immunotherapy and tyrosine kinase inhibitor combinations in metastatic renal cell carcinoma.

EU Panel Confirms Recommendation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer

February 28th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has confirmed its recommendation to approve the use of enfortumab vedotin in adult patients with locally advanced or metastatic urothelial cancer who have received prior platinum-based chemotherapy and a PD-1/PD-L1 inhibitor.

Dr. Iacovelli on the Rationale of the ARIES Trial in Urothelial Cancer

February 25th 2022

Roberto Iacovelli, MD, PhD, discusses the rationale of the phase 2 ARIES trial in urothelial cancer.

Adjuvant Nivolumab Approaches EU Approval for Select High-Risk Muscle-Invasive Urothelial Carcinoma

February 25th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab for use as an adjuvant treatment in adult patients with muscle-invasive urothelial carcinoma with a PD-L1 expression of at least 1% on tumor cells, who are at a high risk of recurrence following radical resection.

Neoadjuvant Atezolizumab/Chemo Shows Encouraging Efficacy in Muscle-Invasive Bladder Cancer

February 24th 2022

The addition of atezolizumab to neoadjuvant gemcitabine and cisplatin generated a high rate of non–muscle-invasive downstaging following radical cystectomy, which correlated with improved relapse-free survival and overall survival in patients with muscle-invasive bladder cancer, according to data from a phase 2 trial.

Neoadjuvant Enfortumab Vedotin Demonstrates Encouraging Activity in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

February 19th 2022

Enfortumab vedotin produced promising antitumor activity when used as neoadjuvant treatment in patients with muscle invasive bladder cancer who were not eligible for cisplatin.

ASCO GU 2022: Breaking Down Bladder Cancer Results With Drs. Jonathan Rosenberg and Guru Sonpavde

February 19th 2022

OncLive® speaks with Drs. Jonathan Rosenberg and Guru Sonpavde on the groundbreaking research being presented in bladder cancer.

Frontline Olaparib/Durvalumab Misses PFS End Point in Platinum-Ineligible Metastatic Urothelial Carcinoma

February 19th 2022

The addition of olaparib to durvalumab did not result in a significant prolongation in progression-free survival compared with durvalumab alone in patients with previously untreated, platinum-ineligible metastatic urothelial carcinoma.

Addition of Sacituzumab Govitecan to Pembrolizumab Produces Promising Antitumor Activity in Metastatic Urothelial Cancer

February 19th 2022

Second-line sacituzumab govitecan plus pembrolizumab generated promising antitumor activity in patients with checkpoint inhibitor–naïve metastatic urothelial cancer.

Niraparib Plus Cabozantinib Shows Early Promise in Advanced Urothelial and Kidney Cancer

February 18th 2022

Niraparib in combination with cabozantinib demonstrated a manageable safety profile, with preliminary efficacy observed in heavily pretreated patients with metastatic urothelial carcinoma.

Dr. Petrylak on the Utilization of Enfortumab Vedotin in MIBC

February 18th 2022

Daniel P. Petrylak, MD, discusses the utilization of enfortumab vedotin-ejfv in patients with muscle-invasive bladder cancer (MIBC).

Dr. Iacovelli on Efficacy Findings From the ARIES Trial in Urothelial Cancer

February 18th 2022

Roberto Iacovelli, MD, PhD, discusses efficacy findings from the phase 2 ARIES trial in urothelial cancer.

Frontline Avelumab Misses 1-Year OS Mark, But Shows Notable Activity in Cisplatin-Ineligible, PD-L1+ Advanced Urothelial Cancer

February 18th 2022

Avelumab failed to demonstrate an improvement in overall survival at 1 year as frontline treatment in patients with cisplatin-ineligible, PD-L1–positive advanced urothelial cancer, though it did elicit a notable objective response rate.

Frontline Maintenance Avelumab Shows Consistent OS Benefit in Advanced Urothelial Cancer

February 18th 2022

The frontline maintenance combination of avelumab plus best supportive care continued to show an improvement in overall survival compared with BSC alone in patients with metastatic urothelial cancer who receive first-line chemotherapy.

Addition of Lenvatinib to Pembrolizumab Fails to Improve Survival in Advanced Urothelial Carcinoma

February 18th 2022

The combination of lenvatinib and pembrolizumab elicited comparable antitumor activity compared with placebo plus pembrolizumab as frontline therapy in patients with advanced urothelial carcinoma who were ineligible for platinum-based chemotherapy, according to data from LEAP-011.